Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.

ABSTRACT:

Rationale & objective

Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder that leads to kidney failure and has few treatment options. Metformin is well tolerated and safe in other patient populations. The primary objective of this clinical trial was to determine the safety and tolerability of metformin in patients with ADPKD and without diabetes mellitus.

Study design

Prospective randomized controlled double-blind clinical trial.

Setting & participants

51 adults aged 30-60 years with ADPKD, without diabetes, and an estimated glomerular filtration rate (eGFR) 50-80 mL/min/1.73 m².

Exposure

Metformin (maximum dose 2,000 mg/d) or placebo for 12 months.

Outcome

Coprimary end points were the percentage of participant

SUBMITTER: Brosnahan GM 

PROVIDER: S-EPMC8837717 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature